Search Results - "Clendeninn, N J"

Predictors of optimal virological response to potent antiretroviral therapy by POWDERLY, W. G, SAAG, M. S, CHAPMAN, S, YU, G, QUART, B, CLENDENINN, N. J

“…Current potent antiretroviral therapy (using a protease inhibitor and two nucleoside reverse transcriptase inhibitors) produces a durable suppression of HIV…”
Get full text

Polyglutamation of methotrexate: is methotrexate a prodrug? by CHABNER, B. A, ALLEGRA, C. J, CURT, G. A, CLENDENINN, N. J, BARAM, J, KOIZUMI, S, DRAKE, J. C, JOLIVET, J

Get full text

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration by JODRELL, D. I, BOWMAN, A, RYE, R, BYRNE, B, BODDY, A, RAFI, I, TAYLOR, G. A, JOHNSTON, A, CLENDENINN, N. J

“…2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337), a specific inhibitor of…”
Get full text

The pharmacology and clinical use of methotrexate by Jolivet, J, Cowan, K H, Curt, G A, Clendeninn, N J, Chabner, B A

Get more information

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder by KHORSAND, M, LANGE, J, FEUN, L, CLENDENINN, N. J, COLLIER, M, WILDING, G

“…Oral piritrexim (PTX), a second generation antimetabolite, has been shown to be an active agent against methotrexate refractory transitional cell cancer (TCC)…”
Get full text

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion by O'DWYER, P. J, LAUB, P. B, GALLO, J. M, DEMARIA, D, QIAN, M, REILLY, D, GIANTONIO, B, JOHNSTON, A. L, WU, E. Y, BAUMAN, L, CLENDENINN, N. J

“…AG331 (N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2, 6-diaminobenz-[c,d]-indole glucuronate) is a lipophilic thymidylate synthase inhibitor with activity in…”
Get full text

Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration by Feun, L G, Gonzalez, R, Savaraj, N, Hanlon, J, Collier, M, Robinson, W A, Clendeninn, N J

“…A phase II trial of piritrexim (2,4-diamino-6[2,5-dimethoxybenzyl]-5-methyl pyrido-[2,3d] pyrimidine, 301U74; PTX) was conducted for patients with metastatic…”
Get more information

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks by ROBERTS, J. D, SHIBATA, S, PARADISO, L. J, CLENDENINN, N. J, SPICER, D. V, MCLEOD, H. L, TOMBES, M. B, KYLE, B, CARROLL, M, SHEEDY, B, COLLIER, M. A, PITHAVALA, Y. K

“…To identify a recommended phase II dose for the second generation glycinamide ribonucleotide transformylase (GARFT) inhibitor, AG2034, administered by…”
Get full text

Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma by Feun, L G, Robinson, W A, Savaraj, N, Gonzalez, R, Liebmann, A, Offenhauser, K, Clendeninn, N J

“…A Phase II trial was conducted in patients with metastatic malignant melanoma with DTIC 250 mg/m2 intravenously for 5 days alternating monthly with Piritrexim…”
Get more information

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach by Vokes, E E, Haraf, D J, McEvilly, J M, Mick, R, Kozloff, M F, Goldman, M D, Moran, W J, Clendeninn, N J, Collier, M A, Weichselbaum, R R

“…To increase the complete remission (CR) rate achieved with two cycles of cisplatin, continuous infusion fluorouracil (5-FU) and oral leucovorin (PFL) we added…”
Get more information

Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate by CURT, G. A, JOLIVET, J, CARNEY, D. N, BAILEY, B. D, DRAKE, J. C, CLENDENINN, N. J, CHABNER, B. A

“…We have characterized the determinants of methotrexate (MTX) responsiveness in eight patient-derived cell lines of small-cell lung cancer (SCLC). Clonogenic…”
Get full text

Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule by ADAMSON, P. C, BALIS, F. M, MISER, J, ARNDT, C, WELLS, R. J, GILLESPIE, A, ARONSON, L, PENTA, J. S, CLENDENINN, N. J, POPLACK, D. G

“…Piritrexim, an orally administered, lipid-soluble antifolate, was evaluated in a multi-institutional phase I trial in children. The starting dose was 10…”
Get full text

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma by BERLIN, J, KING, A. C, TUTSCH, K, FINDLAY, J. W, KOHLER, P, COLLIER, M, CLENDENINN, N. J, WILDING, G

“…Renal cell carcinoma exhibits chemoresistance attributable in part to the P-glycoprotein drug efflux mechanism. Acrivastine is a hydrophylic antihistamine that…”
Get full text

Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies by Feun, L G, Savaraj, N, Benedetto, P, Hanlon, J, Sridhar, K S, Collier, M, Richman, S, Liao, S H, Clendeninn, N J

“…A phase I trial of piritrexim was conducted by use of a prolonged, low-dose oral schedule. A number of different regimens were tested, including daily dosing…”
Get more information

A phase II study of piritrexim in patients with advanced squamous head and neck cancer by Uen, W C, Huang, A T, Mennel, R, Jones, S E, Spaulding, M B, Killion, K, Havlin, K, Keegan, P, Clendeninn, N J

“…Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process…”
Get more information

Oral piritrexim : a phase II study in patients with advanced soft tissue sarcoma by SCHIESEL, J. D, CARABASI, M, MAGILL, G, CASPER, E, CHENG, E, MARKS, L, FEYZI, J, CLENDENINN, N. J, SMALLEY, R. V

Get full text

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion by SCHILSKY, R. L, RATAIN, M. J, JANISCH, L, VOGELZANG, N. J, SOL LUCAS, V, RAVITCH, J, HOHNEKER, J. A, CLENDENINN, N. J, TUTTLE, R. L

“…502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems. In the present phase…”
Get full text

Drug resistance in cancer by Curt, G A, Clendeninn, N J, Chabner, B A

Get more information

Initial clinical trial and pharmacokinetics of Thymitaq (AG337) by 10-day continuous infusion in patients with advanced solid tumors by Creaven, P J, Pendyala, L, Meropol, N J, Clendeninn, N J, Wu, E Y, Loewen, G M, Proefrock, A, Johnston, A, Dixon, M

“…To establish the maximum tolerated dose (MTD), dose-limiting and other major toxicities and the major pharmacokinetic parameters of a 10-day infusion of the…”
Get full text

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer by Gore, L., Lewis, K., Von Hoff, D. D., Weiss, G. J., Ramanathan, R. K., Adjei, A. A., Dy, G. K., Ma, W. W., Clendeninn, N. J., Leffingwell, D. P., Sheedy, B., Iverson, C., Miner, J. N., Shen, Z., Yeh, L., Dubowy, R. L., Jeffers, M., Rajagopalan, P., Weekes, C. D.

“…Abstract only…”
Get full text